Cargando…

Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy

Relapsed/refractory acute lymphoblastic leukemia (ALL) is a leading cause of death by cancer in children. Our institution has switched relapse treatment strategy to improve survival. We reviewed records of first relapse/refractory childhood ALL between 1996 and 2012. Based on length of first remissi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceppi, Francesco, Duval, Michel, Leclerc, Jean-Marie, Laverdiere, Caroline, Delva, Yves-Line, Cellot, Sonia, Teira, Pierre, Bittencourt, Henrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025146/ https://www.ncbi.nlm.nih.gov/pubmed/27632202 http://dx.doi.org/10.1371/journal.pone.0160310

Ejemplares similares

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Clinical response to dabrafenib and chemotherapy in clonally-related histiocytosis and acute lymphoblastic leukemia
por: Hubert, Gervaise, et al.
Publicado: (2022)

Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children
por: Benadiba, Joy, et al.
Publicado: (2018)

Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study
por: Athale, Uma H., et al.
Publicado: (2017)

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2018)

Case report: Success of allogeneic hematopoietic stem cell transplantation for refractory systemic-onset juvenile idiopathic arthritis
por: Beaufils, Camille, et al.
Publicado: (2023)

2699. Pneumococcal Vaccination During Chemotherapy in Children Treated for Acute Lymphoblastic Leukemia
por: Dorval, Sarah, et al.
Publicado: (2019)

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
por: Bhojwani, Deepa, et al.
Publicado: (2019)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

IDH1 as a Cooperating Mutation in AML Arising in the Context of Shwachman-Diamond Syndrome
por: Mourad, Stéphanie, et al.
Publicado: (2019)

Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
por: Williams, Sherry, et al.
Publicado: (2018)

Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001
por: Tran, Thai Hoa, et al.
Publicado: (2022)

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2015)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
por: Zhao, Junmei, et al.
Publicado: (2015)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
por: Uy, Natalie, et al.
Publicado: (2018)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
por: Bertamini, Luca, et al.
Publicado: (2018)

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
por: DeAngelo, Daniel J., et al.
Publicado: (2020)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers
por: Khater, Fida, et al.
Publicado: (2019)

French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia
por: Trioche, Pascale, et al.
Publicado: (2012)

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
por: Laetsch, Theodore W., et al.
Publicado: (2023)

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
por: Gökbuget, N, et al.
Publicado: (2016)

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
por: Hathaway, Lindsey, et al.
Publicado: (2018)

An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia
por: Ma, Jun, et al.
Publicado: (2018)

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
por: Queudeville, Manon, et al.
Publicado: (2017)

Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
por: Topp, Max S., et al.
Publicado: (2020)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023)

Targeted Treatment and Immunotherapy in High-risk and Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia
por: Graiqevci-Uka, Violeta, et al.
Publicado: (2022)

P501: ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS
por: Baruchel, André, et al.
Publicado: (2023)

Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study
por: Sun, Weili, et al.
Publicado: (2018)

Testicular relapse of acute lymphoblastic leukemia()
por: Carolan, Alexandra, et al.
Publicado: (2023)

Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
por: Davis, Tyler, et al.
Publicado: (2013)

Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia'
por: Tong, W H
Publicado: (2016)

Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
por: Garrett, May, et al.
Publicado: (2019)

Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
por: Zheng, Qingqing, et al.
Publicado: (2020)

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Proskorovsky, Irina, et al.
Publicado: (2019)

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
por: Stock, Wendy, et al.
Publicado: (2020)

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
por: Maffini, Enrico, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qkio1h2a7pr3njuthsuf1qk8cu